PMID- 34600133
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 112
DP  - 2021 Nov
TI  - Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy.
PG  - 327-329
LID - S1201-9712(21)00769-4 [pii]
LID - 10.1016/j.ijid.2021.09.061 [doi]
AB  - This article reports a fatal case of human herpesvirus 6 (HHV-6) myelitis 
      following CD19-targeted chimeric antigen receptor T-cell therapy. Infection from 
      HHV-6 reactivation after haematopoietic stem cell transplant is established, and 
      outside of this population is limited to case reports. The patient developed 
      cytokine release syndrome and immune effector cell-associated neurotoxicity 
      syndrome that responded to corticosteroids both clinically and on imaging. 
      Subsequently, ascending flaccid paralysis developed, leading to neuromuscular 
      respiratory failure and, ultimately, death. Disease progression was refractory to 
      foscarnet and multiple immunomodulating agents. HHV-6 should be considered in 
      patients with encephalitis and myelitis after adoptive T-cell therapy.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Handley, Guy
AU  - Handley G
AD  - Department of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of 
      Medicine, Division of Infectious Disease and International Medicine, Morsani 
      College of Medicine, University of South Florida, Tampa, FL, USA. Electronic 
      address: guyhandley@usf.edu.
FAU - Khawaja, Fareed
AU  - Khawaja F
AD  - Department of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Kondapi, Divya S
AU  - Kondapi DS
AD  - Department of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Lee, Hun J
AU  - Lee HJ
AD  - Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Kaufman, Gregory P
AU  - Kaufman GP
AD  - Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Neelapu, Sattva S
AU  - Neelapu SS
AD  - Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Fayad, Luis E
AU  - Fayad LE
AD  - Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Tummala, Sudhakar
AU  - Tummala S
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Chi, Linda
AU  - Chi L
AD  - Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Strati, Paolo
AU  - Strati P
AD  - Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Mulanovich, Victor E
AU  - Mulanovich VE
AD  - Department of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
LA  - eng
PT  - Case Reports
DEP - 20210929
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the 
      International Society for Infectious Diseases
JID - 9610933
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Cell- and Tissue-Based Therapy
MH  - *Herpesvirus 6, Human
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - *Myelitis/drug therapy/etiology
MH  - *Receptors, Chimeric Antigen
OTO - NOTNLM
OT  - CAR T-cell therapy
OT  - Human herpesvirus-6
OT  - Myelitis
EDAT- 2021/10/03 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/10/02 20:12
PHST- 2021/07/07 00:00 [received]
PHST- 2021/08/30 00:00 [revised]
PHST- 2021/09/26 00:00 [accepted]
PHST- 2021/10/03 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/10/02 20:12 [entrez]
AID - S1201-9712(21)00769-4 [pii]
AID - 10.1016/j.ijid.2021.09.061 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2021 Nov;112:327-329. doi: 10.1016/j.ijid.2021.09.061. Epub 
      2021 Sep 29.